Adjuvant therapy in patients with rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and radical resection in pathological stages I-III.
作者信息
Lino-Silva Leonardo S, Zepeda-Najar César, Salcedo-Hernández Rosa A
机构信息
Surgical Pathology, Instituto Nacional de Cancerología, Tlalpan, Mexico City, Mexico.
Surgical Oncology, Hospital Angeles Tijuana, Tijuana, Baja California Norte, Mexico.
出版信息
Ann Transl Med. 2020 Sep;8(17):1116. doi: 10.21037/atm-20-5088.
Abstract
摘要
相似文献
1
Adjuvant therapy in patients with rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and radical resection in pathological stages I-III.对病理分期为I-III期的直肠腺癌患者，在接受新辅助放化疗和根治性切除术后进行辅助治疗。
Ann Transl Med. 2020 Sep;8(17):1116. doi: 10.21037/atm-20-5088.
2
Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.新辅助放化疗和全直肠系膜切除术治疗后，Ⅱ期或Ⅲ期直肠癌患者辅助化疗并不能改善无复发生存。
Dis Colon Rectum. 2020 Apr;63(4):427-440. doi: 10.1097/DCR.0000000000001558.
3
Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.优化辅助奥沙利铂在临床 II 期或 III 期直肠腺癌中的应用。
Oncologist. 2019 Aug;24(8):e671-e676. doi: 10.1634/theoncologist.2018-0333. Epub 2019 Jan 29.
4
Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007.直肠癌新辅助放化疗后术后化疗的应用：1998-2007 年监测、流行病学和最终结果-医疗保险数据的分析。
Cancer. 2014 Apr 15;120(8):1162-70. doi: 10.1002/cncr.28545. Epub 2014 Jan 28.
5
Is an elective diverting colostomy warranted in patients with an endoscopically obstructing rectal cancer before neoadjuvant chemotherapy?在新辅助化疗前，内镜下阻塞直肠的直肠癌患者是否需要选择性横结肠造口术？
Dis Colon Rectum. 2012 Mar;55(3):249-55. doi: 10.1097/DCR.0b013e3182411a8f.
6
Impact of adjuvant chemotherapy after neoadjuvant radio- or radiochemotherapy for patients with locally advanced rectal cancer.新辅助放疗或放化疗后辅助化疗对局部晚期直肠癌患者的影响。
J Cancer Res Clin Oncol. 2017 Nov;143(11):2363-2373. doi: 10.1007/s00432-017-2483-6. Epub 2017 Jul 29.
7
The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy.术前血液单核细胞计数对未接受新辅助放化疗的病理T3N0M0期直肠癌的预后影响
Tumour Biol. 2015 Sep;36(10):8213-9. doi: 10.1007/s13277-015-3560-6. Epub 2015 May 21.
8
[Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].巩固性新辅助治疗或全新辅助治疗后低位直肠癌的保直肠手术：初步报告
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):281-288. doi: 10.3760/cma.j.cn.441530-20200228-00096.
9
Survival among clinical stage I-III rectal cancer patients treated with different preoperative treatments: A population-based comparison.不同术前治疗的临床I-III期直肠癌患者的生存率：基于人群的比较。
Cancer Epidemiol. 2016 Aug;43:35-41. doi: 10.1016/j.canep.2016.06.007. Epub 2016 Jul 4.
10
A single institution's long-term follow-up of patients with pathological complete response in locally advanced rectal adenocarcinoma following neoadjuvant chemoradiotherapy.单机构对局部晚期直肠腺癌新辅助放化疗后病理完全缓解患者的长期随访
Int J Colorectal Dis. 2017 Mar;32(3):341-348. doi: 10.1007/s00384-016-2712-5. Epub 2016 Nov 24.
本文引用的文献
1
Rectal cancer patients with downstaging after neoadjuvant chemoradiotherapy and radical resection do not benefit from adjuvant chemotherapy.接受新辅助放化疗及根治性切除术后分期降低的直肠癌患者无法从辅助化疗中获益。
Ann Transl Med. 2020 Jun;8(12):743. doi: 10.21037/atm-20-1278.
2
Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes.直肠癌的新辅助治疗：治疗结果的系统评价和荟萃分析。
Ann Surg. 2020 Mar;271(3):440-448. doi: 10.1097/SLA.0000000000003471.
3
The relationship between mesorectal grading and oncological outcome in rectal adenocarcinoma.直肠腺癌中直肠系膜分级与肿瘤学结局的关系。
Colorectal Dis. 2019 Mar;21(3):315-325. doi: 10.1111/codi.14535. Epub 2019 Jan 17.
Zotero 插件